Surgery Partners Inc (NASDAQ: SGRY) closed the day trading at $24.71 down -3.74% from the previous closing price of $25.67. On the day, 783802 shares were traded.
Ratios:
For a better understanding of SGRY, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 15.97 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.26. For the most recent quarter (mrq), Quick Ratio is recorded 1.57 and its Current Ratio is at 1.71. In the meantime, Its Debt-to-Equity ratio is 1.54 whereas as Long-Term Debt/Eq ratio is at 1.48.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Barclays on March 06, 2024, initiated with a Equal Weight rating and assigned the stock a target price of $35.
On November 14, 2023, TD Cowen Upgraded its rating to Outperform which previously was Market Perform and also lowered its target price recommendation from $39 to $35.
BofA Securities Upgraded its Neutral to Buy on June 02, 2023, whereas the target price for the stock was revised from $42 to $45.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 14 ’24 when Doherty David T sold 721 shares for $28.59 per share. The transaction valued at 20,613 led to the insider holds 95,719 shares of the business.
Evans Jason Eric sold 4,840 shares of SGRY for $143,796 on Mar 13 ’24. The Chief Executive Officer now owns 459,670 shares after completing the transaction at $29.71 per share. On Mar 12 ’24, another insider, Owens Bradley R., who serves as the National Group President of the company, sold 2,783 shares for $29.82 each. As a result, the insider received 82,989 and left with 78,338 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.14 while its Price-to-Book (P/B) ratio in mrq is 1.57.
Stock Price History:
Over the past 52 weeks, SGRY has reached a high of $45.79, while it has fallen to a 52-week low of $22.05.
Shares Statistics:
A total of 126.59M shares are outstanding, with a floating share count of 72.99M. Insiders hold about 42.35% of the company’s shares, while institutions hold 66.05% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from ARS Pharmaceuticals, Inc. analysts. The consensus estimate for the next quarter is $24.71, with high estimates of $4.45 and low estimates of $1.73.
Analysts are recommending an EPS of between $Industrials and $Industrials for the fiscal current year, implying an average EPS of $Healthcare.
